These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35447552)

  • 21. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Peters S; Gadgeel SM; Mok T; Nadal E; Kilickap S; Swalduz A; Cadranel J; Sugawara S; Chiu CH; Yu CJ; Moskovitz M; Tanaka T; Nersesian R; Shagan SM; Maclennan M; Mathisen M; Bhagawati-Prasad V; Diarra C; Assaf ZJ; Archer V; Dziadziuszko R
    Nat Med; 2024 Jul; 30(7):1923-1932. PubMed ID: 38898120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial Cell-Free DNA Sequencing in
    Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
    JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entrectinib: First Global Approval.
    Al-Salama ZT; Keam SJ
    Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
    Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
    J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL; Macy ME
    Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
    González-Sales M; Djebli N; Meneses-Lorente G; Buchheit V; Bonnefois G; Tremblay PO; Frey N; Mercier F
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):997-1007. PubMed ID: 34536094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
    Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
    Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
    Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
    Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
    Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
    Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
    Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
    Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
    Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.